Please assess the completion status of the following clinical trial:

Trial Title: Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 and ≤ 75 years;~2. Primary tumour was histologically confirmed colorectal adenocarcinoma;~3. Together with clinical or radiological evidence of first occurrence of non-resectable liver-only metastases~4. With evidence of tumor RAS gene mutant status;~5. With at least one measurable tumor.~6. Performance status (ECOG) 0\~1~7. A life expectancy of ≥ 3 months~8. Adequate hematological function: Neutrophils≥1.5 x109/l and platelet count≥100 x109/l; Hb ≥9g/dl (within 1 week prior to randomization)~9. Adequate hepatic and renal function: Serum bilirubin≤1.5 x upper limit of normal (ULN), alkaline phosphatase ≤5x ULN, and serum transaminase (either AST or ALT) ≤ 5 x ULN(within 1 week prior to randomization);~10. Written informed consent for participation in the trial.~Exclusion Criteria:~1. Previous exposure to target therapy, chemotherapy, radiotherapy or intervention therapy for colorectal liver metastases.~2. Known or suspected extrahepatic metastases.~3. Patients with known hypersensitivity reactions to any of the components of the study treatments.~4. Having previously participated in a study which included a possibility of being allocated to avastin therapy (whether or not the patient actually received avastin)~5. Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or left ventricular ejection fraction (LVEF) below the institutional range of normal~6. Acute or sub-acute intestinal occlusion~7. Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding~8. Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~9. Known drug abuse/ alcohol abuse~10. Legal incapacity or limited legal capacity~11. Pre-existing peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ARM A (Type: EXPERIMENTAL): patients received avastin in combination with mFOLFOX6
- ARM B (Type: ACTIVE_COMPARATOR): Patients received mFOLFOX6 alone

Based on this trial design, predict the completion outcome and termination type (if applicable).